Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis
Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis
复制标题
DOI：
10.1016/j.cca.2007.07.023
复制
发表时间：
2007-11-01
影响因子：
5
通讯作者：
Koike, Takao
中科院分区：
文献类型：
--
作者：
Ieko, Masahiro;Nakabayashi, Toru;Koike, Takao
背景：纤维蛋白单体(Fm)及其复合体(SFC)在高凝状态的血液中含量较高。最近开发了两种新的SFC免疫分析方法(SF和FMC)。方法：检测103例DIC和血栓性疾病患者的血栓标志物浓度。结果：FMC的浓度约为SF的3.35倍。在FMC/SF比值高的患者中，FDP和D-二聚体浓度升高，提示SFC浓度的差异是由纤溶活性引起的。此外，这些患者的血浆样本在使用F405进行的Western blotting分析中发现，除了FM和SFC外，还含有FM的X-和Y-纤维，F405与这些片段结合。在体外研究中，含有EDTA的混合血浆形成的FM被纤溶活性降解为FM的X-和Y-片段，我们称之为FM降解产物(FMDP)。结论：FMDP的测定对诊断与纤溶相关的血栓形成状态有重要意义，如在DIC患者中，它可能是一种有用的高凝状态和加速纤溶的标志物。(C)2007 Elsevier B.V.保留所有权利。
Background: Fibrin monomer (FM) and its complex (sFC) exist at high concentrations in hypercoagulable state blood. Two novel immunoassays for sFC (SF and FMC) using specific monoclonal antibodies (IF-43 and F405) were recently developed.Methods: We measured the concentrations of thrombotic markers in 103 patients with DIC and thrombotic disorders.Results: We found that the concentration of FMC was approximately 3.35-fold greater than that of SF. In patients with a high FMC/SF ratio, FDP and D dimer concentrations were increased, suggesting that the discrepancy in sFC concentrations was caused by fibrinolytic activity. Further, plasma samples from those patients were found to contain the X- and Y-firagments of FM in addition to FM and sFC in a Western blotting assay using F405, which binds with those fragments. In an in vitro study, FM formed from pooled plasma containing EDTA was degraded to the X- and Y-fragments of FM by fibrinolytic activity, and we termed those FM degradation, products (FMDP).Conclusion: Determination of FMDP is important for diagnosis of thrombogenic conditions associated with fibrinolysis, such as in patients with DIC, and it may serve as a useful marker for hypercoagulable states with accelerated fibrinolysis. (C) 2007 Elsevier B.V. All rights reserved.